Overview

Deferment of Imaging for Pulmonary Embolism

Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
Background. Management of patients with suspected Pulmonary Embolism (PE) is problematic if diagnostic imaging is not available. Pretest Clinical Probability (PCP) and D-dimer (D-d) assessment were shown to be useful to identify those high risk patients for whom empirical, protective anticoagulation is indicated. To evaluate whether PCP and D-d assessment, together with the use of low molecular weight heparins (LMWHs), allow objective appraisal of PE to be deferred for up to 72 hours, we planned to prospectively evaluate consecutive patients with suspected PE. Methods. In case of deferment of diagnostic imaging for PE, patients identified at high-risk (those with high PCP or moderate PCP and positive D-d), receive a protective full-dose treatment of LMWH; the remaining patients will be discharged without anticoagulant. All patients will be scheduled to undergo objective tests for PE within 72 hours. Standard antithrombotic therapy will be then administered when diagnostic tests confirmed Venous ThromboEmbolism (VTE).
Phase:
Phase 4
Details
Lead Sponsor:
Azienda Ospedaliera Universitaria Policlinico
Treatments:
Dalteparin
Heparin
Heparin, Low-Molecular-Weight
Tinzaparin